In summary, whileGLP-1medications have been found to be helpful in thetreatmentof Type 2 diabetes and reduction of cardiovascular mortality, for individuals witheatingdisordersor disorderedeatingbehaviors, these drugs can be harmful when not used for their intended purpose, when inadequately monitored or monitored by clinicians withouteatingdisorderexpertise, or when used for ...
Feb1, 2025 ·This is a systematic review and meta-analysis of the beneficial effects ofGLP-1analogsoneatingdisorders, with a particular emphasis on anthropometric variables andeatingbehaviors in BED.
Feb 17, 2026 ·GLP-1use can mask symptoms of restrictiveeatingdisorders, because many common effects (rapid weight loss, nausea, and reduced appetite) overlap. “For some people witheatingdisordersor in recent recovery, use of these drugs can be risky.
Feb 4, 2026 ·Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact witheatingdisorders.
Jun 3, 2025 ·Penn Medicine Princeton Centerfor EatingDisordersis an inpatient program for patients aged 8 to adult with acuteeatingdisorders. Patients benefit fromtreatmentfor the physical, psychosocial, and nutritional aspects of theireatingdisorder, but they also have immediate access to full-service care for any other medical needs.
Radkhah et al. published the first systematic review and meta-analysis on the efficacy ofGLP-1analogsin thetreatmentofeatingdisorders[83]. In this publication, they confirmed the efficacy ofGLP-1in managing BED, revealing that patients receivingGLP-1agonists experienced greater weight loss compared to controls.
